Pfizer to buy weight-loss drug developer Metsera
Thomas Fuller | SOPA Images | Lightrocket | Getty Images Pfizer stated on Monday it might purchase weight-loss drug developer Metsera in a deal valued up to $7.3 billion, together…
Shares of under-the-radar weight-loss drug play could double: Leerink
Leerink Partners sees a rosy outlook forward for Metsera . The funding agency initiated protection of the biopharma inventory at an outperform score. Leerink’s worth goal of $77 implies shares…